Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2011-07-26
2011-07-26
Kaushal, Sumesh (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C435S325000, C435S455000, C536S023100, C536S023400, C530S350000, C530S351000
Reexamination Certificate
active
07985582
ABSTRACT:
DNA plasmids containing sequences coding for different fragments of 185neuoncoprotein which are able to induce an immune response against p185neu-overexpressing tumors, and pharmaceutical compositions thereof are described.
REFERENCES:
patent: 2002/0177551 (2002-11-01), Terman
patent: 2005/0129715 (2005-06-01), Paterson et al.
patent: WO 00/44899 (2000-08-01), None
patent: WO 2004/041065 (2004-05-01), None
patent: WO 2005/039618 (2005-05-01), None
Chi-Chen Lin, et al., “Therapeutic HER2/Neu DNA Vaccine Inhibits Mouse Tumor Naturally Overexpressing Endogenous Neu”, Molecular Therapy, vol. 10, No. 2 Aug. 2004, pp. 290-301.
A. Amici, et al., “DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2
eu transgenic mice”, Gene Therapy(2000) 7, 703-706.
Claudia Curcio, et al., “Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2
eu carcinomas”, The Journal of Clinical Investigation, Apr. 2003, vol. 111, No. 8, pp. 1161-1170.
Joon Youb Lee, et al., “Comparison of the antitumor efficacies of Her-2
eu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice”, Vaccine 21 (2003) 521-531.
Elena Quaglino, et al., “Concordant morphologic and gene expression data show that a vaccine halts HER-2
eu preneoplastic lesions”, The Journal of Clinical Investigation, vol. 113, No. 5, Mar. 2004, pp. 709-717.
M.A. Liu, “DNA vaccines: a review”, Journal of Internal Medicine, 2003, 253: 402-410.
Abstract, Cancer immunoprevention: tracking down persistent tumor antigens, P.L. Lollini, et al., Trends Immunol., Feb. 24, 2003(2):62-6 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab., H.S. Cho, et al., Nature, Feb. 13, 2003, 421(6924):756-60 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, The biology of erbB-2
eu/HER-2 and its role in cancer, N.E. Hynes, et al., Biochim Biophys Acta., Dec. 30, 1994, 1198(2-3):165-84 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissues, M.F. Press, et al., Oncogene, Jul. 5, 1990(7):953-62 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Studies of the HER-2
eu proto-oncogene in human breast and ovarian cancer, D.J. Siamon, et al., Science, May 12, 1989, 244(4905):707-12, (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Existent T-cell and antibody immunity to HER-2
eu protein in patients with breast cancer, M.L. Disis, et al., Jan. 1, 1994, 54(1):16-20, (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2
eu-derived peptide, G.E. Peoples, et al., Proc. Natl. Acad. Sci. USA, Jan. 17, 1995, 92(2), 432-6 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2
eu transgenic mice, A. Amici, et al., Gene Ther., Apr. 7, 2000, 7(8), 703-6 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice, S. Rovero, et al., J. Immunol., Nov. 1, 2000, 165(9), 5133-42 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors, Y. Chen, et al., Cancer Res., May 1, 1998, 58(9), 1965-71 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2
eu transgenic mice, E. Quaglino, et al., Cancer Res., Apr. 15, 2004, 64(8), 2858-64 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA, W.Z. Wei, et al., Int. J. Cancer, May 31, 1999, 81(5), 748-54 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammory tumor growth without anti-ErbB-2 antibody, J. Immunol., Sep. 15, 2001, 167(6), 3201-6 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2, M.P. Piechocki, et al., J. Immunol., Sep. 15, 2001, 167(6), 3367-74 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, The collaboration of both humoral and cellular HER-2
eu-targeted immune responses is required for the complete eradication of HER-2
eu-expressing tumors, R.T. Reilly, et al., Cancer. Res., Feb. 1, 2001, 61(3), 880-3 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2
eu carcinomas, C. Curcio, et al., J. Clin. Invest., Apr. 2003, 111(8), 1161-70 (www.ncbi.nlm.nih.gov/sites/entrez).
Abstract, DNA vaccines: a review, M.A. Liu, J. Intern. Med., Apr. 2003, 253(4), 402-10 (www.ncbi.nlm.nih.gov/sites/entrez).
Amici Augusto
Cavallo Federica
Forni Guido
Marchini Cristina
Quaglino Elena
Kaushal Sumesh
Porzio, Bromberg & Newman P.C.
LandOfFree
Plasmids coding for p185 neu protein sequence variants and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Plasmids coding for p185 neu protein sequence variants and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasmids coding for p185 neu protein sequence variants and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684065